Navigation Links
Ceremed Awarded Third NIH Grant to Develop Soluble Hemostatic Carriers for Targeted Delivery of Therapeutic Agents to the Surgical Site
Date:10/4/2010

LOS ANGELES, Oct. 4 /PRNewswire/ -- Ceremed, Inc. was awarded a Small Business Innovation Research (SBIR) grant, the company's third in a series of grants from the National Institutes of Health to develop a versatile soluble carrier with bone hemostatic properties for targeted delivery of therapeutic agents directly to surgical sites. The recently awarded grant will aid Ceremed in its effort to develop a soluble carrier to topically deliver the antibiotic Vancomycin.

Topical delivery of therapeutics is a valuable tool in securing better patient outcomes, particularly in many common cardiac, orthopedic, spinal, and neurosurgical procedures. Ceremed's anhydrous, soluble, and highly malleable carrier is made of proprietary AOC® material. Applied to cut bone, the AOC® carrier will control bleeding and release therapeutic agents as it dissolves without compromising the healing process.

The AOC® formulation with Vancomycin, in combination with a carrier for the antibiotic Gentamicin, under development thanks to an earlier NIH grant, will target both susceptible and methycillin-resistant (MRSA) organisms to help prevent post operative infections, reduce the cost of potentially preventable complications, and improve patient outcomes across surgical fields. The third grant in the series was awarded for the development of an AOC® carrier for DBM. AOC® with DBM allows for stable delivery of bone growth factors directly to the bone, strengthens bone fusion, and promotes significantly earlier onset of healing and postoperative recovery without increased risk of complications.

"Utilizing the AOC® material for delivery of therapeutics has great potential to continue improving patient outcomes across surgical fields," said Ceremed's Chairman Tadeusz Wellisz, MD. "Ceremed has experienced success in developing soluble carriers for DBM and Gentamicin, and we look forward to continued success in the development of AOC® Vancomycin."

About AOC®:

AOC® is Ceremed's proprietary implantable polymer material. It is composed of a blend of Alkylene Oxide Copolymers that are commonly used in the medical field. This unique blend is an ideal carrier because it dissolves without swelling and is eliminated from the body within 48 hours. To dissolve, the material does not require metabolic or inflammatory processes as most resorbable polymers do.  AOC® is synthetic and can be formulated in a range of consistencies with a unique combination of properties, including anhydrous formulations, making it an ideal carrier for compounds that are not stable in aqueous solutions. The material is proving to be a versatile, soluble carrier that delivers a broad range of therapeutics to the surgical site, without compromising the healing process.

AOC® is already used in spinal fusion products, as a soluble coating system for orthopedic and neurosurgical implants, and for bone hemostasis. Ceremed is able to custom-manufacture compounds using any OEM proprietary material in combination with the AOC® biomaterial.

About Ceremed:

Ceremed, Inc. is a privately held medical device corporation founded in Los Angeles, California in 2002.  Ceremed's mission is to utilize its proprietary implantable polymer formulations to enhance the "Standard of Care" by replacing aging and possibly harmful materials with safe and effective materials and devices that bring about better patient outcomes by improving healing and reducing post-surgical complications.  The company manufactures a variety of surgical implantable devices marketed both directly and through partnership licensing and manufacturing arrangements. Ceremed's signature product is the highly successful Ostene® Bone Hemostasis material (www.ostene.com).

Research leading to the formulation of AOC carriers was supported by NIH Awards # 1R43HL092732, 1R43 HL104840, and 1R41AR056177 from the National Institute Of Arthritis And Musculoskeletal And Skin Diseases and from the National Heart, Lung and Blood Institute. The studies were solely the responsibility of Ceremed, Inc. and do not necessarily represent the official views of the National Institutes of Health.


'/>"/>
SOURCE Ceremed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ceremeds OSTENE(R) Improves Bone Fusion and Healing After Surgery, New Study Shows
2. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
3. Twin City Pharmacy & Surgical Awarded NJHPCO 2010 Pharmacists of the Year
4. Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
5. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
6. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
7. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
8. Sysmex America Awarded National Novation GPO Contract for Automated Urinalysis
9. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
10. CRF Health is Awarded for Getting Closer
11. SRI International and Stanford University School of Medicines MISTRAL Collaborative and the Institute for Pediatric Innovation Awarded FDA Grant to Accelerate Commercialization of Pediatric Medical Devices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... excited to announce the launch of its Mediceutical line of products, a line of ... of clinical conditions. Founded in 2013, Forté spent more than two years researching and ... http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/2/2016)... , May 2, 2016 Kalorama Information ... (Electronic Medical Records) market in a recent white paper.  ... switches, Increased physician usage, a growing market are among ... noted in Kalorama,s report EMR 2016: The ... marks Kalorama,s seventh complete study of the EMR industry, ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
Breaking Medicine Technology:
(Date:5/3/2016)... ... May 03, 2016 , ... Diagnotes, a ... Tidelands Health, a three hospital system in South Carolina, to provide its secure ... for technology that enhances communication, drives workflow efficiencies and improves provider and patient ...
(Date:5/3/2016)... ... 2016 , ... Nationally recognized personal injury law firm Monge & Associates is honoring ... anyone who wants one for their Mother or any other mother figure. , According to ... Mothers.” Monge goes on to say, “we are choosing to do this by giving ...
(Date:5/3/2016)... Los Angeles, CA (PRWEB) , ... May 03, 2016 , ... ... Massage Chair with its user friendly Samsung tablet and exclusive Smart Application. The ... truly unbeatable massage. Starting each massage with a customized user profile and specialized massage ...
(Date:5/3/2016)... , ... May 03, 2016 , ... ... one of Canada’s top Information and Communication Technology (ICT) companies in the annual ... Multinational ICT companies operating in Canada, as ranked by revenue. , “We ...
(Date:5/3/2016)... ... 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick Pospisil, now ... used to diagnose and treat joint problems. During this procedure, Dr. Pospisil makes a ... lighting system and lens that illuminate and magnify the various structures in the joint ...
Breaking Medicine News(10 mins):